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Exosome enrichment of human serum using
multiple cycles of centrifugation
In this work, we compared the use of repeated cycles of centrifugation at conventional
speeds for enrichment of exosomes from human serum compared to the use of ultra-
centrifugation (UC). After removal of cells and cell debris, a speed of 110 000 × g or
40 000 × g was used for the UC or centrifugation enrichment process, respectively. The
enriched exosomes were analyzed using the bicinchoninic acid assay, 1D gel separation,
transmission electronmicroscopy,Western blotting, and high-resolution LC-MS/MS anal-
ysis. It was found that a five-cycle repetition of UC or centrifugation is necessary for suc-
cessful removal of nonexosomal proteins in the enrichment of exosomes from human
serum. More significantly, 5× centrifugation enrichment was found to provide similar
or better performance than 5× UC enrichment in terms of enriched exosome protein
amount, Western blot band intensity for detection of CD-63, and numbers of identified
exosome-related proteins and cluster of differentiation (CD) proteins. A total of 478 pro-
teins were identified in the LC-MS/MS analyses of exosome proteins obtained from 5×
UCs and 5× centrifugations including many important CD membrane proteins. The
presence of previously reported exosome-related proteins including key exosome protein
markers demonstrates the utility of this method for analysis of proteins in human serum.
Keywords:
Centrifugation / Exosomes / Human serum / Mass spectrometry / Ultracentrifu-
gation DOI 10.1002/elps.201500131
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Exosomes are small endosomal derived membrane mi-
crovesicles (30–100 nm in diameter) secreted by most cell
types. Exosomes are found in many biological fluids, such
as blood [1, 2], urine [3–7], saliva [8, 9], and breast milk [10].
Exosomes have received much attention recently since exo-
somes are believed to have important roles in intercellular
communications [11]. There are several recent review papers
in the literature providing an overview of the current status
of exosome research [12–16], among which Simpson and his
co-workers [12] provided proteomic insights and diagnostic
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potentials of exosomes and reported 24 proteins commonly
identified in most exosome studies.
The most common exosome enrichment method in-
volves using ultracentrifugation (UC) at high speeds such
as 110 000 × g. Prior to the UC, whole cells and large cell
debris are removed by low-speed centrifugations or by filtra-
tion using a 0.22 m filter. UC is performed one [17, 18],
two [19–22], or three times [23], where the supernatant is re-
moved followed by addition of a buffer solution after eachUC.
After the initial UC, density-gradient UC using sucrose [22]
or iodixanol [2, 23] is often applied to improve the purity of
exosomes. UC on a sucrose cushion has also been performed
to isolate exosomes [24, 25].
There are several commercially available kits used to en-
rich exosomes such as the Total Exosome Isolation kit (Life
Technologies) [26], ExoQuick (System Bioscience) [10,21,27],
Exo-spin (Cell Guidance System) [28], and PureEXO (101Bio).
An immunoaffinity pull-downmethod can also be performed
where an exosome-specific antibody is used to selectively en-
rich exosomes [7]. Recently, two types of antibodies on photo-
sensitizer beads were utilized to perform a rapid and sensitive
Colour Online: See the article online to view Scheme 1 and Fig. 2 in
colour.
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• 4 mL, 2 mL, or 1 mL human serum
• Dilution with PBS buffer (1:1)
• 2,000 × g, 30 min, 4oC 
• 12,000 × g, 45 min, 4oC
Pretreatment
• Repeated (3× or 5× ) Ultracentrifugation (110,000 × g)
or Centrifugations (40,000 × g) at 4οC
• Final volume of exosomes: 100μL 
Enrichment
• Without lysis
• BCA assay (40 μL)
• 1D gel analysis (8 μL)
• TEM analysis (3 μL)
• With lysis
• Western blot analysis (10 μL)
• LC-MS/MS analysis (20 μL)
Analysis
Scheme 1. Summary of the current investigation.
detection of extracellular vesicles including exosomes [29].
A filtration device has also been used to enrich exosomes
where ultrafiltration devices with 10 000 Damolecular weight
(MW) cut-off membranes were used [30]. Field-free fraction-
ation [31] or size-exclusion chromatography where particles
are separated based on their size has also been applied to
enrich exosomes.
A combination of two or more enrichment methods has
often been used to isolate exosomes with varying degrees
of success. These may include UC with ExoQuick precipita-
tion [10], size exclusion chromatography with immunoaffin-
ity [32], filtration using a 100 000 MW cut-off filter with
UC [33, 34], filtration using a 100 000 MW cut-off filter with
the application of a commercial enrichment kit [35], filtra-
tion using 100 000 MW cut-off filter with immunoaffinity
and UC [18], filtration using 100 000 MW cut-off filter with
sucrose density-gradientUC, orUC followed by a commercial
kit [36]. However, exosome enrichment from human serum
using UC or a commercial kit often suffers from impuri-
ties [24, 25], due to the presence of high abundant proteins
such as albumin and immunoglobulin G in human serum.
Although density-gradient (DG) UC is often used to improve
the purity, it is a relatively long (18 h) process [2, 10].
Recently, three different isolationmethods (DG, UC, and
EpCAM-based immunoaffinity pull-down (EI)) were com-
pared for isolating exosomes from normal human plasma,
where a total of 213 exosome proteins were identified [2].
The authors mentioned that DG was superior in isolating
pure exosomes since it successfully removed highly abun-
dant plasma proteins compared to the other two techniques.
The LC-MS/MS analyses revealed 148 (69.5%), 78 (36.6%),
and 39 (18.3%) exosome proteins from DG, UC, and EI,
respectively.
In the current study, we have explored the application of
centrifugation at a speed of 40 000 × g, which is much more
affordable and accessible to most scientists than that of UC
and whether it can enrich exosomes from a human serum
sample comparable to that obtained by UC. Centrifugation at
40 000 × gwas applied three and five times to study the effect
of multiple cycles of centrifugation. The results from cen-
trifugation were compared with those from conventional UC
based on several methods including 1D gel analysis, trans-
mission electron microscopy (TEM), Western blotting, and
LC-MS/MS analysis on a high-resolutionOrbitrapmass spec-
trometer (see Scheme 1). It was found that centrifugation at
40 000 × g could provide comparable or improved results rel-
ative to UC by using multiple cycles of centrifugation. The
current results show that the exosome enrichment can be
successfully achieved in a rather inexpensive centrifuge in-
strument.
2 Materials and methods
2.1 Materials
Pooled normal human serum samples were obtained from
Innovative Research (Novi, MI, USA). Anti-CD63 antibody
(ab59479, Mouse monoclonal to CD63), goat anti-mouse IgG
H&L (horseradish peroxidase) preadsorbed (ab97040) were
from Abcam (Cambridge, MA). PBS (P-5368) was obtained
from Sigma-Aldrich (St. Louis, MO, USA).
2.2 Exosome enrichment—pretreatment of serum
The serum sample was first diluted with an equal volume of
PBS buffer solution to decrease viscosity. The diluted serum
sample was then centrifuged at 2000 × g for 30 min at 4°C.
The supernatant was transferred into 1 mL tubes and cen-
trifuged at 12 000 × g for 45 min at 4°C. The supernatant was
filtered through a 0.22mfilter to remove any remaining cell
particles or cell debris.
2.3 Exosome enrichment—UC
UCwas performed using a BeckmanOptima XL-70Ultracen-
trifuge with a speed of 110 000× g at 4°C for 120min (the first
UC step) or 70 min (the subsequent UC steps). Ultra-ClearTM
tubes (catalog number: 344057, from Beckman Coulter) were
used with an SW 55 Ti rotor in the process of UC. The total
volume of each tube was limited to 4.0 mL to avoid any over-
flowing or contamination during sample preparation steps.
Five consecutive UC steps were performed to improve
the purity of exosomes obtained. For the exosomes obtained
starting from 4.0 mL serum (corresponding to 8.0 mL of 2×
diluted serum), the two pellets were combined after the first
UC. For the exosomes obtained starting from 1.0 mL serum
(2.0 mL of 2× diluted serum), 2.0 mL PBS buffer was added
to the tube containing 2.0mL of 2× diluted serumprior to the
first UC step. After each UC step, supernatant was removed,
followed by addition of 4 mL PBS buffer. After the fifth UC
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step, the pellet was resuspended in 100 L PBS buffer after
the supernatant was removed.
2.4 Exosome enrichment—centrifugation
Centrifugation to enrich exosomes was performed using a
Sorvall Stratos Centrifuge from Thermo at a speed of 40 000
× g (20 762 rpm) at 4°C for 120 min (first run) or 70 min
(for subsequent runs) with a microcentrifuge tube (Axygen
MCT-175-L-C) from Axygen.
For exosomes prepared from1.0mL serum (2.0mL of 2×
diluted serum), two tubeswere usedwhere each tube contains
1.0 mL of 2× diluted serum. For exosomes prepared from
2.0 mL serum, three tubes were used where each tube con-
tains 1.33 mL of 2× diluted serum. For exosomes prepared
from 4.0 mL serum, six tubes were used where each tube
contains 1.33 mL of 2× diluted serum. After the first UC, the
pellets were combined. After each centrifugation, 1.2mL PBS
buffer was added to the pellet after removing the supernatant.
After the fifth centrifugation step, the pellet was resuspended
in 100 L PBS buffer.
2.5 Quantitation and gel analysis
The total protein concentration in the supernatants and in
the final pellet was determined using the bicinchoninic acid
(BCA) assay (Pierce Biotechnology, Pittsburgh, PA, USA),
where two of 20L for each sample were used. For the 1D gel
analysis, sample (8 L) was mixed with a lane marker nonre-
ducing sample buffer (5×) from Thermo Scientific Pierce
(catalog number: PI-39001), followed by incubation at 70°C
for 10 min. Electrophoresis was then performed on a mini-
proteanTGXprecast gel (Bio-Rad) at 90V for 10min, followed
by 200 V for 25 min. The gel was stained with the Sigma
silver staining kit following the manufacturer’s instruction.
2.6 TEM analysis
Carbon film (CFTH200-Cu) was obtained from Electron Mi-
croscopy Sciences (Hatfield, PA, USA). Glow discharge on
the carbon film was performed to make the surface of the
carbon film hydrophilic. The sample (3 L) was then loaded
on the carbon film and incubated for 2 min. After remov-
ing the supernatant liquid by absorbing it using filter paper,
5 L of 2.5% w/v glutaldehyde in PBS was loaded for the
fixation of the exosomes. After 5-min incubation, the super-
natant liquid was removed and the carbon film was washed
with water three times. After removing the last water, the film
was stained with 5 L of 1% uranyl acetate for 1 min. The
TEM image was obtained using a CM-100 TEM instrument
from Philips.
2.7 Lysis and Western blotting
The lysis of the enriched exosomes involved incubation of
the exosomes at 4°C for 30 min in a 1:1 ratio with a 2×
RIPA buffer. The 2× RIPA buffer solution was composed of
100mMTris-HCl, 300mMNaCl, 2.0%NP-40 (USBiological),
1.0% sodium deoxychlorate, 0.2% SDS, 1 mM EDTA, and
protease inhibitors (cOmplete, EDTA-free Protease Inhibitor
Cocktail Tablets, Roche).
For Western blot analysis, the lysed exosome proteins
(20 L each) were separated on a gel as described above and
transferred onto a PVDF membrane (catalog number: 162–
0177, Bio-Rad). The membrane was then first incubated in
PBS blocking buffer containing 5% milk for 1 h at room
temperature and then with primary mouse anti-CD63 (cat-
alog number: ab59479, Abcam) diluted in a 1:500 ratio in
PBST (0.1% Tween 20 in PBS buffer solution) overnight
at 4°C. The membrane was then washed three times with
PBST and incubated with secondary goat anti-mouse IgG
H&L (horseradish peroxidase) preadsorbed (ab97040, Ab-
cam) in PBST (1:1000 dilution) and visualized by incubat-
ing sections with 3,3-diaminobenzidine tetrahydrochloride
(ImmPACT DAB peroxidase substrate; Vector Laboratories,
Burlingame, CA, USA)
2.8 Tryptic digestion
Following the lysis of the exosome samples, the filter-aided
sample preparation (FASP)methodwas used to perform tryp-
tic digestion. The lysed sample was reduced with 100 mM
DTT for 10 min at 70°C. The solution was allowed to cool
down and thenwasmixed with 200L of 8Murea in 100mM
Tris-HCl (pH 8.5), transferred to a centrifugal spin filter with
a MW cutoff of 30 kDa (YM-30, Millipore), and centrifuged
for 15 min at 14 000 × g. The same centrifugation conditions
were used for the following steps: The sample was washed
again with 200 L of the urea buffer. Alkylation was per-
formed by adding 100L of 50mM iodoacetamide in the urea
buffer, followed by vortexing for 1 min and incubation for 20
min in the dark at room temperature. To remove the remain-
ing iodoacetamide, the protein mixture was centrifuged and
washed twice with the urea buffer. The sample was washed
three times with 100 L of 50 mM ammonium bicarbonate.
Then, tryptic digestion was performed overnight at 37°C by
adding trypsin (Sequencing grade modified, Promega) in a
1:20 ratio w/w. Digested peptides were collected by centrifu-
gation with 40 L of 50 mM ammonium bicarbonate three
times. After tryptic digestion, the samples were desalted us-
ing Thermo Scientific Pierce C18 Spin Columns before LC-
MS/MS analysis.
2.9 LC-MS/MS analysis
The samples were analyzed in duplicate. For each LC-MS/MS
analysis, 0.5 g exosome proteins were used. Peptide
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mixtures dissolved in 0.5% formic acid (FA) were loaded onto
a Proxeon Easy-nLC II system (Thermo) with a flow rate of
400 nL/min. The samples were first desalted on an RP trap
column (100 m × 20 mm, C18AQ particles, 5 m, 200 A˚,
Michrom Bioresources, Auburn, CA, USA) and separated on
a C18 analytical column (75m× 250mm, C18AQ particles,
5 m, 200 A˚) coupled to an Orbitrap Elite mass spectrome-
ter (Thermo Fisher Scientific, San Jose, CA, USA). Peptides
were separated with 0.1% FA in water (solvent A) and 0.1%
FA in ACN (solvent B) using a 70-min linear gradient from 5
to 35% solvent B at a flow rate of 400 nL/min.
The mass spectrometer was operated in positive ion
mode with an electrospray voltage of +2.5 kV and a capillary
temperature of 300°C. Full scan mass spectra were acquired
from m/z 400.0–1800.0 in the Orbitrap analyzer with a res-
olution R = 120 000, followed by HCD MS/MS scans with
resolution R = 15 000 on the top 15 most intense ions. The
isolation width was set to 1.5 and the normalized collision
energy was 35.0%. Dynamic exclusion was enabled with a
±10 ppm exclusion window with a repeat count of 1 using an
exclusion duration of 30 s.
All MS/MS spectra were searched against the human
UniProt database (downloaded June, 2014) containing 26 152
entries using SEQUEST (Proteome Discoverer 1.4, Thermo
Fisher Scientific). The search parameters were as follows:
(1) static carbamidomethylation of cysteine residues (+57.021
on Cys); (2) dynamic oxidation of methionine residues
(+15.995 onMet); (3) allowing twomissed cleavages; (4) pep-
tide ion mass tolerance 10 ppm (Isotopic MW); (5) fragment
ion mass tolerance 0.6 Da (Isotopic MW). Identified peptides
were filtered using a 1% false discovery rate.
2.10 Ingenuity Pathway Analysis (IPA)
IPA (Ingenuity Systems) was performed to obtain the detailed
molecular information. The identified protein lists were up-
loaded into the IPA tool and analyzed. The result files con-
tained gene symbols, descriptions, locations, and types of
the proteins. The location has four different categories, such
as extracellular, cytoplasm, plasma membrane, nucleus, and
other.
2.11 CD antigen list and comparison
The common cluster of differentiation (CD) antigen
list was obtained from the cdlist on UniProt (http://www.
uniprot.org/docs/cdlist) released on July 9, 2014. The CD
antigen list from CD1 through CD363 was used for compar-
ison. A total of 445 entries from the common CD antigen
list were used for comparison where some CD antigens have
more than one entry; for example CD235a and CD235b. The
Swiss-Prot entry names from the common CD antigen list
and from the currently identified protein list were compared
to obtain the CD antigen name for each identified protein in
the currently identified protein list.
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Figure 1. 1D gel images for the samples from (A) ultracentrifu-
gation and (B) centrifugation processes of 2.0 mL human serum.
The samples from 1 through 5 (U1–U5 and C1–C5) are the super-
natants from the corresponding enrichment processes. The sam-
ples of U6 and C6 are from the enriched exosomes. The samples
of 1 and 2 were diluted 500-fold and 20-fold with a PBS buffer so-
lution prior to loading to reduce their concentrations and provide
weaker bands.
3 Results
3.1 Enrichment of exosomes
Currently, the most common enrichment method of exo-
somes is using UC with a speed of 110 000 × g. In this study,
we have explored whether a reduced speed (e.g. 40 000 × g)
would provide similar performance for the enrichment of ex-
osomes. Figure 1 shows the 1D gel images of the samples
obtained from the UC and centrifugation procedures for the
enrichment of exosomes from 2.0 mL human serum. Sam-
ples 1 through 5 are from the supernatants from the first
through the fifth enrichment steps while sample 6 is from
the enriched exosome pellet. The enriched exosome proteins
were visualized using silver-staining. As shown in Fig. 1,
the protein separation patterns for the corresponding sam-
ples of supernatants and enriched exosomes betweenUC and
centrifugation were very similar, showing that these two en-
richment methods provided similar efficiencies for exosome
enrichment.
The concentrations of the first, second, and third super-
natants for both UC and centrifugation were 50, 1, and
0.01 mg/mL, respectively, based on the BCA assay. In the
fourth and fifth supernatant samples, no protein was detected
using BCA assay. Most proteins are believed to be eliminated
after four UC steps or centrifugation steps. Few bands
were still visualized on gel using sliver-staining (Fig. 1),
which illustrates 3× UC enrichment or 3× centrifugation
enrichment is not sufficient to remove nonexosomal proteins.
3.2 Exosome protein yield
The amount of exosome proteins obtained from 1, 2, or 4 mL
human serum was around 2.2, 14.3, or 28.5 g, respectively,
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Table 1. Quantities of exosomes obtained from 2 mL serum
using 5× ultracentrifugations and 5× centrifugations
Sample number Ultracentrifugation (g) Centrifugation (g)
1 3.4 4.3
2 4.0 5.6
3 7.5 7.8
4 10.9 9.7
5 11.3 11.5
6 12.7 14.7
Average ± SD 8.3 ± 4.0 8.9 ± 3.9
A B 5× ultracentrifugations  5 × centrifugations
200 -
150 -
100 -
75 -
50 -
37 -
25 -
20 -
kDa
CD63
200 -
150 -
100 -
75 -
50 -
37 -
25 -
20 -
kDa
CD63
1    2    3 1    2    3
Figure 2. Western blot analyses detecting CD63 in exosomes pu-
rified from human serum using (A) the ultracentrifugation enrich-
ment for five times and (B) the centrifugation enrichment for five
times. The columns of “1,” “2,” and “3” for each image are from
the exosome proteins obtained from 4, 2, and 1mL human serum,
respectively.
from the 3×UC enrichment and 2.1, 8.3, or 20.7 g from the
5×UCenrichment while 3.8, 8.6, or 21.1g from the 3× cen-
trifugation enrichment, and 2.9, 8.5, or 16.3 g from the 5×
centrifugation enrichmentwas obtainedusing theBCAassay.
Around 20% less exosome proteins were observed from the
five-cycle enrichment process compared to the correspond-
ing three-cycle enrichment process. Based on the amount
of exosome proteins obtained from 2 mL serum where both
enrichment methods provided a similar yield of 8.5 g
proteins (Table 1), the current yield is around 0.005%, as-
suming the protein concentration in human plasma is 60 
80 mg/mL. The yields from all the enrichment conditions in
this study were within the reasonable range between 0.001
and 0.01% [1, 37].
3.3 Western blot analysis
Figure 2 shows the Western blot analyses detecting CD63 in
the exosome proteins isolated from human serum using UC
or centrifugation, where the intensities of the bands become
weaker as the starting amount decreases. Similar intensities
in Western blot analysis were observed from the UC and
centrifugation enrichment procedures for the same starting
amounts of exosome proteins, confirming the similar per-
formances between UC and centrifugation. The broad band
50 kDa is characteristic of CD63 [19, 26]. In the cur-
rent investigation, CD63 was only detected when the
Figure 3. TEM images of exosome samples enriched fromhuman
serum using 5× ultracentrifugations and 5× centrifugations. The
first, second, and third rows show the images for the exosomes
enriched from starting amounts of 1, 2, and 4 mL, respectively.
Scale bars: 100 nm.
exosome proteins were not reduced. In additional Western
blot analyses, CD9 and CD81 were also detected from
reduced exosomes proteins and nonreduced proteins,
respectively (data not shown).
3.4 Size distribution of exosomes
Figure 3 shows the TEM images of the enriched exosome
samples from different starting amounts using either 5×
UCs or 5× centrifugations. Exosomes were observed in a size
range of around 100 nm. The number of exosomes increased
with all experimental conditions as the amount of starting
serum increased.
Figure 4 shows the histograms of size distribution of
exosomes enriched from human serum using 5× UCs and
5× centrifugations. The size distributions from the 5× UCs
and 5× centrifugations were found to be very similar where
the average diameters of the purified exosomes were 72 (±21)
nm and 73 (±20) nm, respectively.
3.5 Application of FASP
The FASP method has recently been published for the suc-
cessful digestion of the sample containing SDS, where SDS
is exchanged to urea on a standard filtration device [38, 39].
In the digestion of exosome proteins, in-gel digestion is fre-
quently used since in-gel digestion can circumvent problems
associated with SDS [30, 40].
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Figure 4. Histograms showing the diame-
ter distribution of exosomes enriched from
4 mL human serum using (A) 5× ultracen-
trifugation enrichment and (B) 5× centrifu-
gation enrichment. The total number of ex-
osome particles used for each histogram is
shown as “n”.
51 313 114
Ultracentrifugation
Identified proteins: 364
Plasma membrane proteins: 79 (21.7%)
Centrifugation
Identified proteins: 427
Plasma membrane proteins: 100 (23.4%)
Plasma membrane proteins: 9 (17.6%) Plasma membrane proteins: 30 (26.3%), 
including 8 CD proteins
Plasma membrane proteins: 70 (22.4%), 
including 29 CD proteins.
Total identified proteins: 478
Plasma membrane proteins: 109 (22.8%)
Figure 5. Venn diagram showing the overlap
of exosome proteins enriched from 5× ultra-
centrifugations and 5× centrifugations. A to-
tal of 37 CD proteins were identified.
In the current investigation, protease inhibitors were
added during the lysis step to avoid any protease activity
during lysis. The protease inhibitors in the sample also
inhibit trypsin activity. With the application of the FASP
method, we successfully digested the exosome proteins,
while without the use of the FASP method, the digestion
was not successful. The successful digestion using the FASP
method appears to be due to the protease inhibitors along
with detergents such as SDS and NP-40 being removed
during the filtration processes.
3.6 Proteins identified from LC-MS/MS analysis
A total of 478 proteins were identified from the LC-MS/MS
analyses of exosome proteins enriched from 4 mL serum
using 5× UCs and 5× centrifugations. Figure 5 shows the
Venn diagram showing the overlap of exosome proteins
enriched using 5× UCs or 5× centrifugations, where 313
proteins (65.5%) were commonly observed in both enrich-
ment processes. The complete list of the 478 proteins can
be found in Supporting Information Table 1. The total num-
ber of plasma membrane proteins is 109, where 9 plasma
membrane proteins were only observed from the exosomes
enriched using 5× UCs and 30 plasma membrane pro-
teins were only observed from the exosomes enriched using
5× centrifugations.
Among the 478 proteins, 196 proteins (41.0%) were iden-
tified with a single unique peptide of each protein. The high
mass accuracy of an Orbitrap Elite mass spectrometer (pep-
tide ion mass tolerance  10 ppm) and high peptide confi-
dence level (false discovery rate 1%) are believed to be suf-
ficient to provide a confident peptide list and corresponding
protein list even with a single unique peptide for the identifi-
cation of proteins. The proteins identified with single unique
peptides are assumed to be low-abundance proteins [41].
CD antigens are cell surface molecules recognized by
specific monoclonal antibodies [42]. CD antigens are defined
when surface molecules on human cells interact with at least
one new monoclonal antibody [43]. CD antigens perform a
variety of roles in immune reactions of organisms [44]. A total
of 37 CD proteins were identified from 5× centrifugations,
while 29 CD proteins were identified from 5× UCs (Table 2).
Additional identification of CD proteins from the centrifu-
gation purification process showed that the centrifugation is
more efficient in isolating exosomes than the UC. The de-
tailed information of the 37 CD proteins and their related
peptides are shown in Table 2 and Supporting Information
Table 2, respectively. The MS/MS spectra of the identified
peptides from the 37 CD proteins are included in Supporting
Information Fig. 1.
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Table 2. List of 37 CD proteins identified in the current investigation
Number CD number Swiss-Prot name Accession number Gene name Description na) Ub) Cc)
1 CD9 CD9_HUMAN P21926 CD9 CD9 antigen 5 V V
2 CD10 NEP_HUMAN P08473 MME Neprilysin 1 -d) V
3 CD11b ITAM_HUMAN P11215 ITGAM Integrin alpha-M 1 -d) V
4 CD13 AMPN_HUMAN P15144 ANPEP Aminopeptidase N 7 V V
5 CD18 ITB2_HUMAN P05107 ITGB2 Integrin beta-2 4 -d) V
6 CD29 ITB1_HUMAN P05556 ITGB1 Integrin beta-1 12 V V
7 CD31 PECA1_HUMAN P16284 PECAM1 Platelet endothelial cell adhesion
molecule
4 V V
8 CD36 CD36_HUMAN P16671 CD36 Platelet glycoprotein 4 6 V V
9 CD41 ITA2B_HUMAN P08514 ITGA2B Integrin alpha-IIb 26 V V
10 CD42a GPIX_HUMAN P14770 GP9 Platelet glycoprotein IX 4 V V
11 CD42b GP1BA_HUMAN P07359 GP1BA Platelet glycoprotein Ib alpha chain 2 V V
12 CD42c GP1BB_HUMAN P13224 GP1BB Platelet glycoprotein Ib beta chain 4 V V
13 CD43 LEUK_HUMAN P16150 SPN Leukosialin 1 V V
14 CD45 PTPRC_HUMAN P08575 PTPRC Receptor-type tyrosine-protein
phosphatase C
3 V V
15 CD47 CD47_HUMAN Q08722 CD47 Leukocyte surface antigen CD47 3 V V
16 CD49b ITA2_HUMAN P17301 ITGA2 Integrin alpha-2 4 -d) V
17 CD49f ITA6_HUMAN P23229 ITGA6 Integrin alpha-6 19 V V
18 CD53 CD53_HUMAN P19397 CD53 Leukocyte surface antigen CD53 1 V V
19 CD59 CD59_HUMAN P13987 CD59 CD59 glycoprotein 3 V V
20 CD61 ITB3_HUMAN P05106 ITGB3 Integrin beta-3 27 V V
21 CD63 CD63_HUMAN P08962 CD63 CD63 antigen 2 V V
22 CD66b CEAM8_HUMAN P31997 CEACAM8 Carcinoembryonic antigen-related cell
adhesion molecule 8
1 -d) V
23 CD71 TFR1_HUMAN P02786 TFRC Transferrin receptor protein 1 23 V V
24 CD82 CD82_HUMAN P27701 CD82 CD82 antigen 2 -d) V
25 CD91 LRP1_HUMAN Q07954 LRP1 Prolow-density lipoprotein
receptor-related protein 1
11 V V
26 CD92 CTL1_HUMAN Q8WWI5 SLC44A1 Choline transporter-like protein 1 5 V V
27 CD98 4F2_HUMAN P08195 SLC3A2 4F2 cell-surface antigen heavy chain 1 V V
28 CD107a LAMP1_HUMAN P11279 LAMP1 Lysosome-associated membrane
glycoprotein 1
2 -d) V
29 CD107b LAMP2_HUMAN P13473 LAMP2 Lysosome-associated membrane
glycoprotein 2
1 V V
30 CD148 PTPRJ_HUMAN Q12913 PTPRJ Receptor-type tyrosine-protein
phosphatase eta
7 V V
31 CD151 CD151_HUMAN P48509 CD151 CD151 antigen 2 V V
32 CD156c ADA10_HUMAN O14672 ADAM10 Disintegrin and metalloproteinase
domain-containing protein 10
13 V V
33 CD225 IFM1_HUMAN P13164 IFITM1 Interferon-induced transmembrane
protein 1
1 V V
34 CD233 B3AT_HUMAN P02730 SLC4A1 Band 3 anion transport protein 17 V V
35 CD240CE RHCE_HUMAN P18577 RHCE Blood group Rh(CE) polypeptide 1 -d) V
36 CD241 RHAG_HUMAN Q02094 RHAG Ammonium transporter Rh type A 1 V V
37 CD321 JAM1_HUMAN Q9Y624 F11R Junctional adhesion molecule A 3 V V
a) Number of identified unique peptides.
b) Detection in the samples from 5× ultracentrifugations.
c) Detection in the samples from 5× centrifugations.
d) Not detected.
3.7 Comparison with other identified proteins
Comparison of the 213 human plasma exosome proteins
identified from three different isolation methods (DG, UC,
and EI) [2] with the currently identified 479 exosome pro-
teins revealed 108 common exosome proteins as shown in
Supporting Information Table 3. Among the 108 common
exosome proteins, 7 proteins were found to be CD proteins
(CD31, CD41, CD42c, CD61, CD71, CD233, and CD321).
Eleven proteinswere found in all of the five enrichmentmeth-
ods as shown in Table 3. Among the 11 commonly observed
proteins, four proteins (alpha-2-macroglobulin, albumin,
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Table 3. List of 11 proteins identified from all of the five different exosome enrichment methods (two methods in the current
investigation and three methods in the previous investigation from human plasma [2])
Number Swiss-Prot name Gene name Description
1 A2MG_HUMAN A2M Alpha-2-macroglobulin
2 ALBU_HUMAN ALB Albumin
3 FIBA_HUMAN FGA Fibrinogen alpha chain
4 HPT_HUMAN HP Haptoglobin
5 IGJ_HUMAN IGJ Immunoglobulin J polypeptide
6 K2C6A_HUMAN KRT6A Keratin 6A
7 K1C14_HUMAN KRT14 Keratin 14
8 K1C16_HUMAN KRT16 Keratin 16
9 K1C17_HUMAN KRT17 Keratin 17
10 DCD_HUMAN DCD Dermcidin
11 IGLL5_HUMAN IGLL5 Immunoglobulin lambda-like polypeptide 5
371 108
Number of identified proteins in the current 
investigation = 479 
- UC1 (364 proteins, 76.0%)
- C (427 proteins, 89.1%)
- Common in the two methods (313 proteins,65.3%)
Number of identified proteins in the literature = 213
- DG (148 proteins, 69.5%)
- UC2 (78 proteins, 36.6%)
- EI (39 proteins, 18.3%)
- Common in the three methods (30 proteins, 14.1%)
- UC1 (98 proteins, 90.7%)
- C (99 proteins, 91.7%)
- Common in the two methods (89 proteins, 82.4%)
- DG (97 proteins, 89.8%)
- UC2 (45 proteins, 41.7%)
- EI (23 proteins, 21.3%)
- Common in the three methods (17 proteins, 15.7%)
Common all in the five methods = 11 proteins, 10.2%
105
Figure 6. Venn diagram show-
ing the overlap of exosome
proteins enriched from the
current investigation and from
the three different enrichment
methods [2]. UC, ultracen-
trifugation; C, centrifugation;
DG, density gradient; EI,
EpCAM-based immunoaffinity
pull-down.
fibrinogen alpha chain, and haptoglobin) are well-known
abundant plasma proteins [45], which might have been
enriched as impurities. Five proteins (immunoglobulin J
polypeptide, keratin 6A, keratin 14, keratin 16, and keratin
17) were already identified in the exosome fraction of hu-
man parotid saliva [2]. Ten proteins (all proteins except im-
munoglobulin lambda-like polypeptide 5 in Table 3) were also
previously identified in the exosome fraction of normal hu-
man urine [7]. In Fig. 6 is shown the Venn diagram compar-
ing the overlap of exosome proteins from the three different
isolation methods and the current investigation, where 97
(89.8%), 45 (41.7%), and 23 (21.3%) exosome proteins were
from proteins from DG, UC, and EI, respectively.
Among the 24 common exosomal proteins reported by
Simpson and his co-workers [12], 18 proteins were identified
in the current investigation, where 14 proteins were identi-
fied in both the 5× UC and 5× centrifugation procedures
(Table 4). Two proteins (HSP90AB1 and YWHAG) were
only identified from 5× UC and the other two proteins
(HSP90AA1 and PGK1) were only identified from 5×
centrifugations. The other six unidentified proteins were
identified in similar forms as shown in Table 4.
4 Discussion
A recent study showed that a single cycle by UC or the
ExoQuick kit to purify exosomes from human serum was
not sufficient to remove high amounts of albumin and
immunoglobulin G, where it was suggested that two or more
cycles were required to increase exosome purity [24]. Another
study showed that two cycles of UC are not sufficient to
increase the purity of exosomes from nonexosomal protein
contamination in the enrichment of exosomes from human
serum [25]. The current methodology using UC twice for
enriching exosomes may be effective for enriching exosomes
from cells, while for serum or plasma samples, which
contain several high abundant proteins, multiple cycles
(more than 4) of UC or centrifugation are necessary.
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Table 4. Comparison between the 24 commonly identified exosomal proteins [12] and proteins identified in the current analysis
Gene name Description Current analysisa)
ACTB Actin, cytoplasmic 1 U, C
ACTC1 Actin, alpha cardiac muscle 1 U, C
ACTG1 Actin, cytoplasmic 2 ACTN1 (U, C), ACTR2 (C), ACTR3 (C)
ANXA11 Annexin A11 U, C
ANXA6 Annexin A6 U, C
ARF1 ADP-ribosylation factor GTPase-activating protein 1 ARF3 (U, C)
CFL1 Cofilin-1 U, C
ENO1 Alpha-enolase U, C
GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha GNAI2 (U, C), GNAQ (C), GNAZ (C)
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 U, C
HSP90AA1 Heat shock protein HSP 90-alpha C
HSP90AB1 Heat shock protein HSP 90-beta U
HSPA8 Heat shock cognate 71 kDa protein U, C
PDCD6IP Programmed cell death 6-interacting protein U, C
PGK1 Phosphoglycerate kinase 1 C
PKM2 Pyruvate kinase PKM PKMb) (U, C)
RAB5A Ras-related protein Rab-5A RAB5C (U, C)
RAB5B Ras-related protein Rab-5B RAB5C (U, C)
RAB5C Ras-related protein Rab-5C U, C
RAP1B Ras-related protein Rap-1b U, C
YWHAB 14-3-3 Protein beta/alpha U, C
YWHAE 14-3-3 Protein epsilon U, C
YWHAG 14-3-3 Protein gamma U
YWHAZ 14-3-3 Protein zeta/delta U, C
a) U and C mean detection from 5× ultracentrifugation and 5× centrifugation purifications, respectively. For the proteins that were not
identified in the current analysis, the gene names of the identified similar proteins were provided.
b) The alternative name is PKM2.
The TEM image showed that the exosome enrichment
using 5× centrifugations is similar to 5× UCs in removing
proteins and protein aggregates, providing a similar average
diameter of exosomes. There are several advantages to the
use of centrifugation in that a centrifuge instrument is rel-
atively inexpensive and widely disseminated compared to a
UC instrument. In addition, it is easy to handle the samples
without contamination since most tubes for centrifugation
have lids, while extra care is required for sample handling
using UC since most tubes for UC do not have lids.
In conclusion, in the current investigationwehave shown
that five-cycle repetition with the use of UC or centrifugation
is necessary for a successful enrichment of exosomes from
human serumbased on 1Dgel analysis and the comparison of
protein yield between three cycles and five cycles. In addition,
we have shown that 5× centrifugations provided comparable
results to those obtained using 5× UCs. Both enrichment
procedures provided similar performances in terms of exo-
some protein amounts and Western blot analyses detecting
CD-63 antigen, while significantly higher numbers of identi-
fied exosome proteins and CD proteins were obtained from
5× centrifugations. A comparison between the exosome pro-
tein list from the current investigation with the previously
reported exosome protein list shows that the current method
is successful in isolating exosomes from human serum. Ad-
ditionally, a total of 37 CD proteins were identified, which
will be important in future exosome research for providing
a means for rapid detection of exosomes using targeted anti-
bodies or mass spec assays. This will be especially important
in biomarker studies of disease states and therapeutic re-
sponse based on monitoring of proteins from exosomes in
serum.
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